文献速递淋巴瘤

CD47过表达在肠道非生发中心B细胞型弥漫大B细胞淋巴瘤中常见并与18q21获得相关

CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain.
PubMed 文献 · Blood Adv · 2022-01-01

研究对238例弥漫大B细胞淋巴瘤(DLBCL)患者进行CD47、CD8、CD68免疫组化染色,并对37例进行靶向二代测序。肠道DLBCL的CD47高表达比例显著高于其他器官(41.4% vs 8.3%,P < .001),18q21获得/扩增者均为CD47高表达,肠道CD47高表达DLBCL局限于回肠末端至升结肠且均为非生发中心B细胞型。

要点

  • 肠道DLBCL的CD47高表达比例为41.4%(24/58),其他器官为8.3%(15/180),P < .001。
  • 18q21获得/扩增见于10/37例,且全部为CD47高表达。
  • 肠道CD47高表达DLBCL局限于回肠末端至升结肠,且均为非生发中心B细胞型。

核心结论

  • CD47高表达DLBCL与18q21获得/扩增密切相关,且在肠道中患病率高。
  • 作者建议将CD47高表达DLBCL分为肠道型和非肠道型。
  • 需进一步研究以评估此处所见特征组合是否可重复,以及是否足以将原发性肠道DLBCL视为独立的生物学实体。

研究设计与样本

  • 对238例DLBCL患者进行CD47、CD8和CD68免疫组化染色,CD47按强度5级评分,CD8和CD68用QuPath软件定量评估。
  • 对37例患者进行靶向大规模平行测序(二代测序)。

主要发现

  • 按器官定量分析CD8和CD68,肠道DLBCL的细胞毒性T细胞浸润显著低于其他器官(P < .001)。
  • CD47高表达组在肠道DLBCL中为24/58(41.4%),在其他器官DLBCL中为15/180(8.3%)(P < .001)。
  • 18q21获得/扩增见于10/37例,且全部为CD47高表达。
  • 肠道CD47高表达DLBCL发生于回肠末端至升结肠,且局限于非生发中心B细胞型。
  • 生存分析中,非肠道CD47高表达DLBCL的预后差于肠道CD47高表达DLBCL(P = .025)。

临床怎么用

  • 作者提出将CD47高表达DLBCL分为肠道型和非肠道型。
  • 原文未据此给出临床推荐。

局限性

  • 需进一步研究以评估此处所见特征组合是否可重复,以及是否足以将原发性肠道DLBCL视为独立的生物学实体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The CD47/signal regulatory protein α pathway is an emerging immune checkpoint that is a new therapeutic target. We investigated CD47 expression in diffuse large B-cell lymphoma (DLBCL) of various subtypes and organs. Moreover, the relationship between CD47 expression and genetic alterations was analyzed using panel-based massively parallel sequencing (next-generation sequencing [NGS]). CD8, CD68, and CD47 immunohistochemical staining were performed on 238 patients with DLBCL. CD47 was scored according to intensity on a 5-level scale, and CD8 and CD68 were quantitatively evaluated using QuPath software. Panel-based NGS was performed in 37 patients. In CD8 and CD68 quantitative analyses by organs, intestinal DLBCL showed significantly lower cytotoxic T-cell infiltration than that in others (P < .001). The CD47-high group comprised 24 of 58 (41.4%) patients in the group with DLBCL from intestine and 15 of 180 (8.3%) patients in the group with DLBCL from other organs (P < .001). The 18q21 gain/amplification was found in 10 of 37 patients, and all of them were CD47-high. Intestinal CD47-high DLBCL occurred in terminal ileum to ascending colon and was restricted to nongerminal center B-cell type. In the survival analyses, the prognosis of nonintestinal CD47-high DLBCL was poorer than that of intestinal CD47-high DLBCL (P = .025). CD47-high DLBCL was closely associated with 18q21 gain/amplification and showed a high prevalence in intestine. We propose to classify CD47-high DLBCL into intestinal and nonintestinal types. Further studies are necessary to assess whether the constellation of features seen here is reproducible and sufficient to consider primary intestinal DLBCL as a distinct biological entity.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Cho J, Yoon SE, Kim SJ, et al. CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain. Blood Adv. 2022. PMID: 35475881. doi:10.1182/bloodadvances.2021006305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。